And what's the point of speculating phase II anyway??
Sunrise was not sabotaged. It was stopped for futility, and even though the control arm exceeded history, Bavituximab performed below that and placebo.
Bavituximab wasn't making "healthier sick patients" healthier than placebo and control. It failed, no matter how you slice it.
They need to address the admitted 2tonelephant, as the data mining from Sunrise proved.. 70% of therapeutic lost at sea.
The focus should be on solving the riddle:
"the curve of diminishing returns", as related to b2gp1 and availability.
"Lets say you have to much antiPs bavi injected, and as a result less available b2gp1, or more usesless bavi with only one arm grabbing b2gp1, instead of two as required to bind to PS".
Or move on and stop wasting time with big clumsy product.
All the best,
John
Market Data 
Markets 
AI
